At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
Displaying 101–110 of 563 results.
-
The purpose of this study is to assess the safety and effectiveness of the drug mosunetuzumab for people with follicular lymphoma who have not yet received treatment. Mosunetuzumab binds to a cancer cell and a T cell (which plays a key role in the immune system) at the same time. Researchers think that mosunetuzumab may strengthen the immune system's ability to fight cancer cells by activating a patient's own cells to destroy the tumor. Mosunetuzumab is given as a subcutaneous (under the skin) injection.
-
The purpose of this study is to evaluate the safety and effectiveness of cesium-131 (Cs-131) brachytherapy in patients with brain cancer that has come back after prior radiation therapy and who will be having surgery to remove it. Brachytherapy involves the placement of radioactive seeds into the brain during surgery. The seeds remain in place permanently in the area where the tumor was removed and give off cancer-killing radiation temporarily. 
-
The purpose of this study is to find the highest dose of the investigational drug AVA6000 that can be given safely in people with advanced solid tumors that are not responding to treatment. AVA6000 is very similar to a standard chemotherapy drug called doxorubicin. Like doxorubicin, AVA6000 works to slow or stop the growth of cancer cells by blocking an enzyme. Unlike doxorubicin, however, AVA6000 is a "prodrug," meaning it remains inactive until it reaches the site of the cancer. Because of the way AVA6000 works, it may be useful for treating cancer with fewer side effects than doxorubicin. AVA6000 is given intravenously (by vein).
-
Deficient mismatch repair (dMMR) happens when a cell becomes unable to repair mistakes that happen during the normal process of cell division. Standard treatments for early-stage rectal cancer include chemotherapy, radiation therapy, and surgery. In this study, researchers are assessing the safety and effectiveness of giving the investigational immunotherapy dostarlimab first in people with locally advanced mismatch repair-deficient rectal cancer. Doctors will then evaluate patients' response to treatment before considering standard chemoradiation and/or surgery. Patients whose tumors respond completely to dostarlimab alone can be followed with close surveillance and no surgery. 
-
Researchers want to find the best dose of BMS-986393 to use with other drugs to treat multiple myeloma. The people in this study have multiple myeloma that keeps growing or came back after treatment.
-
Daunorubicin, cytarabine, and gemtuzumab ozogamicin are different chemotherapy drugs used to treat acute myeloid leukemia (AML). CPX-351 is made up of daunorubicin and cytarabine. It is created in a way that makes the drugs stay in the bone marrow longer and could be less likely to cause heart problems than traditional anthracycline drugs, a common class of chemotherapy drugs used in cancer care.
-
Researchers are assessing obinutuzumab in people with primary central nervous system lymphoma (PCNSL) whose cancer responded to initial treatment. They want to see if obinutuzumab increases the time without the disease returning or getting worse. This type of treatment is called maintenance therapy.
-
Researchers are finding the best dose of ASP2138 to use in people with advanced digestive cancers. The people in this study have cancer of the pancreas, stomach (gastric cancer), or junction between the esophagus and stomach (gastroesophageal junction cancer). In addition, their cancers make a protein called CLDN 18.2 and keep growing even after treatment.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
Researchers want to see if the drug talquetamab is useful for treating multiple myeloma. The people in this study have multiple myeloma that keeps growing even after treatment. They also recently received a CAR T cell therapy called idecabtagene autoleucel.